NCT06885281

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 112 (estimated)
• Sponsor: Zai Lab (Shanghai) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Detailed description

This is an open-label, multiple-center, phase 1b/2 study of ZL-1310 in selected solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	ZL-1310	drug ZL-1310

Timeline

• Start date: 2025-05-12
• Primary completion: 2027-08-01
• Completion: 2027-12-01
• First posted: 2025-03-20
• Last updated: 2026-04-09

Locations

20 sites across 2 countries: United States, China

Regulatory

• FDA-regulated drug study